Cardiff Oncology (CRDF) Shares Outstanding (2011 - 2026)

Cardiff Oncology has reported Shares Outstanding (Entity) for 15 years, with the latest figure at $68.3 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 43.35% year-over-year to $68.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $68.3 million (up 43.35% YoY) and the FY2025 annual result came in at $68.3 million, up 43.35% from the prior year.
• Shares Outstanding (Entity) climbed to $68.3 million in Q4 2025 per CRDF's latest filing, from $67.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $68.3 million in Q4 2025 and troughed at $37.6 million in Q1 2021.
• A 5-year average of $48.4 million and a median of $44.7 million in 2022 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Entity) jumped 241.05% in 2021, then changed 0.0% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $42.0 million in 2021, then rose by 6.47% to $44.7 million in 2022, then changed by 0.0% to $44.7 million in 2023, then rose by 6.65% to $47.6 million in 2024, then surged by 43.35% to $68.3 million in 2025.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $68.3 million, $67.1 million, and $66.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.